TranXenoGen
Biotechnology company developing an avian transgenic platform to manufacture high-volume recombinant therapeutic proteins in egg albumen, generate transgenic animal models, and support high-throughput antibody production. Activities described include development of non-viral and cell-based transgenic methods, licensing of cloning-related patents, collaborative agreements with third parties, and positioning for contract manufacturing and product development (generic biologics and proprietary therapeutics).
Industries
Nr. of Employees
small (1-50)
TranXenoGen
Northborough, Massachusetts, United States, North America
Products
Generic biologics production (insulin, human serum albumin)
Development and intended manufacture of established therapeutic proteins using the avian transgenic platform to provide alternative supply sources for insulin and human serum albumin.
Proprietary novel therapeutic proteins (anti-cancer program)
Proprietary development program for novel therapeutic proteins, including an anti-neoplastic peptide program described in publications and company materials.
Avian Transgenic Production System
A production platform utilizing the white of transgenic chicken eggs to produce high-volume recombinant therapeutic proteins as an effectively priced alternative.
Insulin
Generic biological product developed using TranXenoGen's avian expression technology platform for established and growing markets.
Direct-Egg Transfection
A non-viral method for the transfection of large transgenes into chicken eggs, enabling transgenic chickens to express recombinant proteins in the albumin fraction of their eggs.
PGC/CEC Stem Cell Technology
Primordial germ cells or chicken embryonic cells are harvested from developing embryos, grown in culture for transfection, and transferred to recipient eggs to produce chimeric chickens.
Generic biologics production (insulin, human serum albumin)
Development and intended manufacture of established therapeutic proteins using the avian transgenic platform to provide alternative supply sources for insulin and human serum albumin.
Proprietary novel therapeutic proteins (anti-cancer program)
Proprietary development program for novel therapeutic proteins, including an anti-neoplastic peptide program described in publications and company materials.
Avian Transgenic Production System
A production platform utilizing the white of transgenic chicken eggs to produce high-volume recombinant therapeutic proteins as an effectively priced alternative.
Insulin
Generic biological product developed using TranXenoGen's avian expression technology platform for established and growing markets.
Direct-Egg Transfection
A non-viral method for the transfection of large transgenes into chicken eggs, enabling transgenic chickens to express recombinant proteins in the albumin fraction of their eggs.
PGC/CEC Stem Cell Technology
Primordial germ cells or chicken embryonic cells are harvested from developing embryos, grown in culture for transfection, and transferred to recipient eggs to produce chimeric chickens.
Services
Development and manufacture of high-volume recombinant therapeutics (including monoclonal antibodies) using an avian transgenic production system; licensing opportunities for platform technologies.
Development and manufacture of high-volume recombinant therapeutics (including monoclonal antibodies) using an avian transgenic production system; licensing opportunities for platform technologies.
Expertise Areas
- Transgenic production systems (avian)
- Recombinant protein manufacturing
- Avian stem cell culture and germline manipulation
- Cloning and sperm-mediated transgenesis
Key Technologies
- Non-viral transfection of avian eggs
- Primordial germ cell (PGC) and embryonic cell manipulation
- Testes-directed (sperm-targeting) transfection
- Somatic cell nuclear reprogramming / cloning methods
News & Updates
Company announced successful expression of monoclonal antibodies in eggs, described as a proof-of-principle milestone for egg-based antibody production.
Notice of allowance in the U.S. for a patent related to genetic manipulation of male germ cells.
Announcement of research/evaluation collaboration with a major therapeutic company to evaluate monoclonal antibody production using the company's platform.
Announcement of a collaboration with Abbott Laboratories to pursue monoclonal antibody production.
Company entered into an agreement with a third party (Advanced Cell Technology) as reported on the partner's site.
Company announced successful expression of monoclonal antibodies in eggs, described as a proof-of-principle milestone for egg-based antibody production.
Notice of allowance in the U.S. for a patent related to genetic manipulation of male germ cells.
Announcement of research/evaluation collaboration with a major therapeutic company to evaluate monoclonal antibody production using the company's platform.
Announcement of a collaboration with Abbott Laboratories to pursue monoclonal antibody production.
Company entered into an agreement with a third party (Advanced Cell Technology) as reported on the partner's site.